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Abstract
Placental chorioangioma is the most common subtype of non-trophoblastic placental tu-
mors. Other subtypes are very rare and usually associated with an uneventful course of 
pregnancy. Most chorioangiomas are small and of no clinical significance. Giant chorio-
angiomas may be associated with serious fetal and maternal complications. So far, no 
established ultrasound guidelines are available for the management of placental non-tro-
phoblastic tumors. This may be attributed to the rarity of the disease entity and its different 
clinical features and complications. In this article, the role of ultrasound findings such as 
the tumor’s size, vascularity, feeding vessels, amniotic fluid and location of the placenta 
in the diagnosis, treatment and follow up of these tumors is presented relying on up-to-
date literature review. Conservative management with serial ultrasound examinations can 
be an adequate method for monitoring small uncomplicated tumors. Ultrasound-guided 
procedures such as amnioreduction and cordocentesis can be used for amelioration of 
complications. Chorioangioma-specific treatment is reserved for complicated cases in the 
second trimester of pregnancy when prematurity is a matter of concern. Endoscopic laser 
ablation is indicated when the feeding vessel is superficial and small. Interstitial laser ab-
lation is helpful when the placenta is located in the anterior uterine wall. Ligation of the 
feeding vessels is preferred when they are large. Alcohol injection should be performed 
away from the vasculature to prevent toxicity. Microcoils should be inserted as near as pos-
sible to the tumor to prevent collateral formation. Ultrasound is also a method of choice 
for monitoring the effectiveness of these procedures.
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Placental chorioangiomas
Non-trophoblastic tumors are the most common neoplasms 
of the placenta. They include chorioangioma, teratoma, leio-
myoma and hepatocellular adenoma(1–3). Chorioangioma is 
the most common subtype. It was first described by Clarke 
in 1798(1). Marchetti described three subtypes of placental 
chorioangioma: angiomatous (capillary), cellular and de-
generative(4). Capillary chorioangioma is the most common 
histological type(5) (Fig. 1). Most chorioangiomas are small 
and of no significant importance. Complications are mostly 
associated with chorioangiomas larger than 4 cm in di-
ameter i.e. giant chorioangioma(6,7). Giant chorioangiomas 
can cause polyhydramnios, intrauterine growth restriction 
(IUGR), placental insufficiency, fetal anemia, non-immuno-
logic hydrop fetalis (NIHF) and intrauterine death(8–10). Due 
to the rarity of the disease, most of the evidence about the 
management of giant placental chorioangioma is based on 
case reports in literature. In the largest retrospective study 
of 22439 placentas, the incidence rate was 0.61% of preg-
nancies(11). The incidence rate of giant chorioangioma is 
rarer and ranges between 1/3500 and 1/9000(7). Asokan et al. 
reported in 1978 for the first time antenatal diagnosis of 
placental chorioangioma by ultrasound(12). Ultrasound is 
the gold standard for prenatal diagnosis and monitoring of 
placental chorioangiomas(13). However, at the moment there 
is no single clinical protocol that may help the physician to 
choose the most appropriate method of treatment of these 
tumors. The aim of this review study is to summarize the ul-
trasound findings of these tumors and their complications. 
The use of certain ultrasound features will be discussed 
for selecting the most appropriate invasive or non-invasive 
method of management.
Gray-scale ultrasound features of placental 
chorioangioma
Chorioangioma usually presents as a single nodule in the 
fetal surface of the placenta near the insertion of the umbili-
cal cord(14) (Fig. 2). Multiple placental chorioangiomas are 
rarer(15). Hyperechogenic areas suggesting hemorrhage as 
well as calcification can be seen. The tumor may contain 
several thin septa(16). The echo pattern of chorioangioma 
is stable(1). The borders of the chorioangioma are well de-
fined(17). The dimensions of the chorioangioma may increase 
during pregnancy or remain the same(8–18). Chorioangioma 
can be overlooked on ultrasound examination even if the 
tumor is large(6). Prenatal diagnosis can also be an inciden-
tal finding during a routine ultrasound examination(19). The 
size may reach several centimeters(20). Chorioangiomas are 
found more often in multiple pregnancies. They are associ-
ated with female gender of the fetus in 72% of cases(11).
Doppler ultrasound assessment of placental 
chorioangioma
Doppler ultrasound is the gold standard for diagnosis of 
placental chorioangioma(21). Substantial vascularity indi-
cates the angiomatous type of chorioangioma(22) (Fig. 3). 
Diagnostic difficulties may arise with cellular and degen-
erative subtypes of chorioangioma where the vasculariza-
tion is less evident(23). Blood vessels of chorioangioma are 
derived from the fetal circulation, so the feeding vessels 
have the same pulsatile flow of the umbilical artery. The 
low resistance of the feeding vessels is related to the ar-
teriovenous shunt(1). The vascularity of chorioangioma is 
one of the prognostic factors for the course of pregnancy. 
Unvascularized chorioangiomas tend to be unrelated to 
complications, while vascularized tumors can predispose 
to typical complications of chorioangioma(24,25).
Ultrasound assessment of the fetus
Measurement of fetal biometry and estimated fetal weight 
is indicated, as chorioangioma is associated with IUGR(1). 
IUGR can be related to placental inefficiency related to 
decreased area of placental tissues required for adequate 
exchange of nutrients(17). Arteriovenous shunt of the blood 
Fig. 1.  Macroscopic appearance of marginal placental chorioan-
gioma
Fig. 2.  Gray-scale ultrasound of giant placental chorioangioma. 
The diameter of the tumor is 70 mm
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and fetal hypoxia caused by unoxygenated blood that by-
passes the maternal circulation through chorioangioma 
can cause high cardiac output and secondary fetal car-
diomegaly(26). Ultrasound features of heart failure include 
enlargement of the heart, decreased contractility and 
pericardial effusion, increased cardiothoracic ratio and 
developing fetal hydrops(8,27). Coincidental presence of 
congenital anomalies with placental chorioangioma have 
been reported(28). Assessment of the middle cerebral artery 
peak systolic velocity MCA-PSV is useful for detecting fe-
tal anemia and high cardiac output failure(26). Not always 
MCA-PSV reflects the severity of fetal anemia. Hellmund 
et al. reported a masked fetal anemia caused by severe 
bilateral hydrothorax which led do decreased ventricu-
lar filling, stroke volume and cardiac output resulting in 
false decreased MCA-PSV. Drainage of the hydrothorax 
by bilateral thoraco-amniotic shunts resulted in reversal 
of the pathological events revealing true high MCA-PSA(29). 
Figure 4 shows the increased multiple of medians (MoM) 
of MCA-PSV as a complication of chorioangioma. Assess-
ment of Doppler flow of umbilical vessels and middle ce-
rebral artery is used for the evaluation of the wellbeing of 
the fetus(8,22,30). 
Ultrasound assessment of the remaining 
placenta, umbilical cord and amniotic fluid
Placentomegaly has an ultrasound association with NIHF 
caused by chorioangioma(29). Polyhydramnios is the most 
common complication of placental chorioangioma oc-
curring in 18–35% of cases of giant chorioangiomas(30). 
Possible transudation of fluid from the vessels together 
with placental deficiency are responsible for polyhydram-
nios(22). Hyperdynamic circulation can cause an increased 
glomerular filtration rate and urine production(25). Poly-
hydramnios, characterized by excess of amniotic fluid, 
can be assessed using the single deepest vertical pocket 
(DVP) or amniotic fluid index (AFI). Polyhydramnios can 
be classified as mild, moderate or severe, when the DVP 
has a value of 8–11 cm, 12–15 cm and above 16 cm re-
spectively. This parameter is simple, and can be a method 
of choice for multiple gestation. AFI Values of 25–30 cm, 
30.1–35 cm, and =>35.1 cm indicate mild, moderate and 
severe polyhydramnios respectively(31). Figure 5 shows 
mild polyhydramnios caused by giant chorioangioma. 
A single umbilical artery and velamentous insertion of the 
umbilical cord have a recognized association with chorio-
angiomas(30) (Fig. 6). 
Three dimensional ultrasound imaging  
of chorioangioma
In three dimensional (3D) ultrasound the surface of cho-
rioangioma is rough and thick(32). Shih et al. reported 
Fig. 3.  Power Doppler ultrasound of placental chorioangioma sho-
wing the vascularity of the mass
Fig. 4.  Assessment of MCA-PSV as an indirect method of detecting fetal 
anemia and heart failure. The MCA-PSV in this patient at 28th 
week of gestation corresponds to 1.7 MoM
Fig. 5.  Maximum pocket volume of 9.4 cm indicating mild polyh-
dramnios
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the use of 3D power Doppler ultrasound for the diag-
nosis and monitoring of giant chorioangioma. The au-
thors could display the angioarchitecture of the tumor, 
confirming the fetal source of blood supply to the tumor. 
This method can show the volume of the mass, as well 
as the vascularity index (VI) of the tumor(16). There is 
a lack of evidence in the literature that 3D ultrasound is 
superior to two dimensional type for the management of 
chorioangioma. 
Ultrasound of maternal pelvis, abdomen  
and breast 
Ultrasound assessment of maternal organs to detect me-
tastases is not indicated, since chorioangioma has no 
malignant potential(1). However, the definitive diagno-
sis of the tumor can only be established by histological 
examination. If the diagnosis is doubtful, especially for 
patients with suspected or confirmed malignant disease, 
imaging diagnostics for the mother is indicated since 
metastases to the placenta and transplacental transfer 
of the neoplastic disease to the fetus have been report-
ed(33). If the diagnosis of chorioangioma is confirmed af-
ter delivery, maternal follow-up with ultrasound is not 
needed(22).
Role of ultrasound in monitoring placental 
chorioangioma
There is no specific protocol for monitoring asymptomatic 
or symptomatic placental chorioangioma. Planned deliv-
ery is the method of choice for term pregnancies compli-
cated by chorioangiomas. When the pregnancy is not in 
term, other methods of treatment should be considered to 
prevent prematurity and reduce complications(5). The mon-
itoring frequency depends on the size of chorioangioma, 
trimester of the pregnancy and associated complications. 
Physicians may consider 3–4-week intervals for small cho-
rioangiomas, while larger tumors should be monitored ev-
ery 1–2 weeks(17). 3D power Doppler can show decrease 
of the vascularization. Decreased VI with simultaneous 
increase of the size of the chorioangioma may reflect the 
hemodynamic changes caused by simultaneous infarction 
of the tumor(16).
Ultrasound-guided procedures  
for amelioration of symptoms caused  
by placental chorioangioma
Ultrasound-guided therapeutic amniocentesis is used for 
reduction of the amount of the amniotic fluid, thereby de-
creasing maternal discomfort and possible complications 
of polyhydramnios, such as premature threatened la-
bor(1,22). Amnioreduction can be repeated in pregnancy(22). 
Ultrasound-guided cordocentesis is indicated to confirm 
fetal anemia, and to transfuse blood to the fetus to cor-
rect it(5). 
Ultrasound-guided procedures used for specific 
treatment of placental chorioangioma
Definite prenatal treatment of placental chorioangioma 
should be reserved for cases with life-threatening compli-
cations, such as NIHF, or when prematurity is a matter 
of concern(8). Doppler ultrasound can help to choose the 
most appropriate procedure depending on the localization 
of the placenta and vascular assessment of the tumor and 
the feeding vessel, its size and distance from the umbilical 
cord(5). Several methods have been described in literature 
for chorioangioma-specific treatment. These include laser 
ablation, alcohol injection, insertion of microcoils, and li-
gation of blood vessels(23,25,34–37). Fetoscopic laser ablation 
seems to be the method of choice for cases where the feed-
ing vessels are small and superficial(21). When the feeding 
vessel of chorioangioma is a secondary branch from the 
umbilical artery, laser photocoagulation can be performed 
without a theoretical risk of placental insufficiency, since 
the umbilical artery does not end in the tumor but con-
tinues to the remaining placenta(8). Interstitial laser ab-
lation might be a choice for cases where the placenta is 
located on the anterior wall, where endoscopic ablation 
can be technically difficult(35). Laser ablation may not be 
suitable for a large feeding vessel, as it may rupture during 
the procedure(34). It is also not applicable when the feed-
ing vessel is deep or when it is near the insertion of the 
umbilical cord because of a risk of injury to the viable pla-
centa(23). Quintero et al. suggested ligation of the arterial 
supply after subchorionic dissection as a choice for larger 
vessels, because of a higher risk of rupture during laser ab-
lation(37). Ercan et al. reported ultrasound-guided injection 
of alcohol directly into the tumor to treat chorioangioma. 
Fig. 6. Velamentous insertion of the umbilical cord
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Knowledge of the angioarchitecture of the tumor is essen-
tial, as alcohol should be injected into the center of chorio-
angioma, away from the vascular structures(25). In case of 
microcoil insertion, caution should be exercised to insert 
as near as possible to the tumor to minimize collateral for-
mation. The technique has no risk of distal embolization of 
the fetal circulation(36). Embolization of the feeding vessels 
has no risk of fetal toxicity, and can be a method of treat-
ment of chorioangioma(5).
Use of ultrasound to monitor the effect  
of treatment of chorioangioma
Ultrasound examination can be used for monitoring the 
effect of the procedures used for the management of cho-
rioangioma or its complications. Ultrasound can be used 
for detecting the remaining amniotic fluid index after 
amnioreduction(22). Doppler ultrasound is used for eval-
uation of the blood flow in the feeding vessels and tumor 
itself. It can show the effectiveness of the procedure by 
showing the absent or decreased blood flow in the feed-
ing vessels and the tumor(25,27). The mass may decrease in 
size, and can develop cystic appearance. Reversal of fea-
tures of NIHF can also be detected(8). Ultrasound is nec-
essary for assessing fetal wellbeing and viability since 
sudden fetal death after surgical interventions have been 
reported(34,37). Mendez-Figueroa et al. reported paradoxi-
cal unexpected development of severe NIHF after amni-
oreduction for chorioangioma-induced polyhdramnios. 
The authors suggested that amnioreduction should be 
performed after laser ablation(34). Increased tumor bed 
blood flow or direct hemorrhage to the tumor due to 
sudden decrease of intrauterine pressure may explain 
the ‘’steal’’ phenomenon(8).
Other non-trophoblastic placental tumors
Placental teratomas are very rare and were described for 
the first time by Morvilli in 1925(38). They are composed of 
derivatives of all three germ layers(2). They resemble fetus 
amorphous, but lack the umbilical cord and central skel-
etal formation of this condition(38). Ultrasound features are 
that of a heteroechogeneous mass. Echogenic foci with 
acoustic shadows represent calcification. Hyperechoic foci 
without acoustic shadows suggest fat(2). Placental terato-
mas are nearly always associated with a normal pregnan-
cy outcome. Large teratomas can press umbilical vessels 
leading to the vessels’ thrombosis(39).
Few cases of placental leiomyoma have been reported 
in literature. Placental leiomyoma may appear as sub-
mucous myoma in the first trimester(40) and has an ap-
pearance of a hypoechoic lesion. Some authors suggest 
that pedunculated uterine leiomyomas are incorporated 
into the placenta during its development. Characteristic 
fetal or maternal waveform by color Doppler may indi-
cate the possibility of myoma existence(3). Placental leio-
myoma may be overlooked during routine ultrasound 
examinations(40). 
Hepatocellular adenoma of the placenta is an extremely 
rare tumor. It remains inconclusive whether this lesion 
represents a neoplasm rather than a rare ectopic or het-
erotopic occurrence(41). It is usually described as a solitary 
tumor like a nodule, involving the placental parenchyma. 
It is usually an incidental finding without a significant 
pathological impact(42). 
Differential diagnosis of placental tumors
Although chorioangioma is the most common type of 
non-trophoblastic placental tumors, ultrasound detection 
of placental tumors should consider other pathological 
conditions in the differential diagnosis. Chorangiocarci-
noma, a complex lesion characterized by torophoblastic 
proliferation within chorioangioma, has similar ultra-
sound features to chorioangioma. Few cases of choran-
giocarcinoma have been reported in literature. In all of 
the reported cases no malignant metastases were report-
ed(43). Confirmation of continuity of feeding vessels with 
the fetal circulation by Doppler ultrasound can exclude 
other pathological conditions like placental hemorrhage, 
maternal lakes, or degenerated myoma(16). In 3D ultra-
sound the walls of a placental cyst or subchorionic he-
matoma are transparent-like structures, and the internal 
texture can be clearly identified(32). The echo pattern of 
blood clots, as opposed to chorioangioma, changes with 
time. A partial mole has a diffuse pattern. Uterine myoma 
can be seen in the maternal surface. Chorioangioma can 
be confused with placental teratoma. The vascularity of 
chorioangioma can differentiate it from teratoma(1). Cal-
cification is more characteristic for teratoma(44). Chorio-
angioma should be differentiated from secondary metas-
tases to the placenta. Malignant melanoma is the most 
common neoplasm metastasizing to placenta during 
pregnancy(33). Ultrasound findings include focal lesions 
with altered echogenicity relative to that of a normal pla-
centa(44).
Summary
No precise management guidelines for the management 
of placental non-trophoblastic tumors have been devel-
oped so far. The lack of guidelines can be related to the 
rarity of this disease entity and the diversity of its clini-
cal features. Treatment modalities for chorioangioma 
are mostly experimental. A systematic literature review 
of chorioangioma may help in establishing a consensus 
for choosing the best method of management(8). Inter-
pretation of ultrasound findings should be carried out 
with caution, as normal findings in the ultrasound do 
not rule out severe complications(29). On the other hand, 
ultrasound imaging of giant chorioangioma does not 
necessarily indicate the presence of fetal and/or mater-
nal complications(14). Placental chorioangioma, even if 
rare, should be considered in the differential diagnosis, 
and looked for carefully when complications typical for 
this tumor, like polyhydramnios and NIHF, are pres-
ent(6). The management of each case of chorioangioma 
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is individual, depending on many factors. Ultrasound 
can detect multiple abnormalities at the same time, and 
the sequence of certain procedures should be considered 
with caution, e.g. amnioreduction after laser ablation(34). 
An ultrasound diagnosis of chorioangioma is only sug-
gestive, and the final diagnosis is established upon 
histological examination of the tumor, which might be 
a malignant neoplasm as well(44). Other non-trophoblas-
tic placental tumors are rare, and usually not related to 
pregnancy complications(39). 
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